|
Vetter is an independent international specialist in the production of aseptically pre-filled injection systems, cartridges and vials. For more than 25 years Vetter has been renowned for its quality, innovation and strategic partnerships. The fact that our products and processes have been approved by the FDA, the EMEA and other authorities ensures the highest level of quality and safety. Vetter provides support for its pharmaceutical and biotech clients from the initial phases of development and regulatory approval process through to the successful product launch and market supply worldwide. Our innovative patented application systems will help your product to attain a decisive edge in the market.
Corporate Headquarters
Vetter Pharma-Fertigung GmbH & Co. KG
Schuetzenstrasse 87
88212 Ravensburg
Germany
Phone: +49 751 3700-0
Fax: +49 751 3700-4000
E-Mail: info@vetter-pharma.com
Internet: http://www.vetter-pharma.com
Headquarters USA
Vetter Pharma-Turm Inc.
Heston Hall/Carriage House Suite 203
1790 Yardley-Langhorne Road
Yardley, PA 19067
Phone: 215-321-6930
Fax: 215-321-6932
E-Mail: info@vetter-pharma.com
Download the company brochure for additional information about Vetter Pharma.
Featured Papers
Uncertainty In Process Control — The Limit Of Setting Limits
Although test procedures used in pharmaceutical quality control have to be validated, these validation experiments are usually performed in early development stages in special laboratories using special equipment by specially skilled analysts. This may lead to an underestimation of the procedure's variability and the setting of inappropriate — in most cases too tight — specification limits.
Know-How Technology Transfer From R&D To Manufacturing
Each product needs to be transferred from R&D scale to commercial manufacturing scale. This requires precise project planning at an early stage, a competent project team, a sophisticated application system, and a filing strategy which meets the time-to-market approach.
Five Keys To Reducing Time-To-Market
With development times measured in years, increasing costs represent a major challenge confronting pharmaceutical and biotechnology companies. As a result,reducing time-to-market is an essential component in any business strategy, particularly when the end of patent protection is considered. One solution is to partner with a contract manufacturer that provides intelligent concepts and the proper experience, not only with respect to the production itself, but also with regulatory authorities. Planning early on is crucial to speeding up the time-to-market process.
Product Lifecycle Management: Maximizing Profit And Leveraging Innovationt
The cost of developing a new drug is continuously rising. Many other factors, such as stricter regulations and stronger global competition, are also creating major challenges. If a pharmaceutical company intends to increase its market share and return on invest ment, it must consider how to maintain a drug‘s profi tability even after its patents have expired. Product Lifecycle Management (PLM) is a viable option for extending profi tability, and there are several methods for ap proaching PLM effectively. What is crucial, how ever, is to plan for it early on, even, if possible, before the drug actually enters the market.
|
